| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider activity in IAM over the last quarter tilts toward buying: insiders added a net 718,750 shares worth roughly $11.5M. In the past 30 days, 1 insider bought and 0 sold. Purchases have clustered in the most recent filings.
Rachlin Evan Lockwood (Director) stands out among recent buyers, now holding an estimated $41.4M in IAM.
Classified under Biotechnology (Healthcare sector), IAM's insider flows are most useful compared with peers in the same group.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 2.59M | $41.41M | +718.8K | |
| Other | 1.86M | - | - | |
| CEO | 1.41M | - | - | |
| Dir | 192.6K | - | - | |
| Other | 71.5K | - | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Oct 16, 2026 | Rachlin Evan Lockwood | Director | Buy | 718,750 | $16.00 | $11,500,000.00 | +38.4% |